904 related articles for article (PubMed ID: 31047902)
1. Efficacy and safety of suspend-before-low insulin pump technology in hypoglycaemia-prone adults with type 1 diabetes (SMILE): an open-label randomised controlled trial.
Bosi E; Choudhary P; de Valk HW; Lablanche S; Castañeda J; de Portu S; Da Silva J; Ré R; Vorrink-de Groot L; Shin J; Kaufman FR; Cohen O;
Lancet Diabetes Endocrinol; 2019 Jun; 7(6):462-472. PubMed ID: 31047902
[TBL] [Abstract][Full Text] [Related]
2. Continuous glucose monitoring for patients with type 1 diabetes and impaired awareness of hypoglycaemia (IN CONTROL): a randomised, open-label, crossover trial.
van Beers CA; DeVries JH; Kleijer SJ; Smits MM; Geelhoed-Duijvestijn PH; Kramer MH; Diamant M; Snoek FJ; Serné EH
Lancet Diabetes Endocrinol; 2016 Nov; 4(11):893-902. PubMed ID: 27641781
[TBL] [Abstract][Full Text] [Related]
3. Study of MiniMed 640G Insulin Pump with SmartGuard in Prevention of Low Glucose Events in Adults with Type 1 Diabetes (SMILE): Design of a Hypoglycemia Prevention Trial with Continuous Glucose Monitoring Data as Outcomes.
De Valk HW; Lablanche S; Bosi E; Choudhary P; Silva JD; Castaneda J; Vorrink L; De Portu S; Cohen O
Diabetes Technol Ther; 2018 Nov; 20(11):758-766. PubMed ID: 30325656
[TBL] [Abstract][Full Text] [Related]
4. Real-time continuous glucose monitoring in adults with type 1 diabetes and impaired hypoglycaemia awareness or severe hypoglycaemia treated with multiple daily insulin injections (HypoDE): a multicentre, randomised controlled trial.
Heinemann L; Freckmann G; Ehrmann D; Faber-Heinemann G; Guerra S; Waldenmaier D; Hermanns N
Lancet; 2018 Apr; 391(10128):1367-1377. PubMed ID: 29459019
[TBL] [Abstract][Full Text] [Related]
5. Effect of initiating use of an insulin pump in adults with type 1 diabetes using multiple daily insulin injections and continuous glucose monitoring (DIAMOND): a multicentre, randomised controlled trial.
Beck RW; Riddlesworth TD; Ruedy KJ; Kollman C; Ahmann AJ; Bergenstal RM; Bhargava A; Bode BW; Haller S; Kruger DF; McGill JB; Polonsky W; Price D; Toschi E;
Lancet Diabetes Endocrinol; 2017 Sep; 5(9):700-708. PubMed ID: 28711468
[TBL] [Abstract][Full Text] [Related]
6. Impact of flash glucose monitoring on hypoglycaemia in adults with type 1 diabetes managed with multiple daily injection therapy: a pre-specified subgroup analysis of the IMPACT randomised controlled trial.
Oskarsson P; Antuna R; Geelhoed-Duijvestijn P; Krӧger J; Weitgasser R; Bolinder J
Diabetologia; 2018 Mar; 61(3):539-550. PubMed ID: 29273897
[TBL] [Abstract][Full Text] [Related]
7. Use of sensor-integrated pump therapy to reduce hypoglycaemia in people with Type 1 diabetes: a real-world study in the UK.
Choudhary P; de Portu S; Arrieta A; Castañeda J; Campbell FM
Diabet Med; 2019 Sep; 36(9):1100-1108. PubMed ID: 31134668
[TBL] [Abstract][Full Text] [Related]
8. Closed-loop insulin delivery in suboptimally controlled type 1 diabetes: a multicentre, 12-week randomised trial.
Tauschmann M; Thabit H; Bally L; Allen JM; Hartnell S; Wilinska ME; Ruan Y; Sibayan J; Kollman C; Cheng P; Beck RW; Acerini CL; Evans ML; Dunger DB; Elleri D; Campbell F; Bergenstal RM; Criego A; Shah VN; Leelarathna L; Hovorka R;
Lancet; 2018 Oct; 392(10155):1321-1329. PubMed ID: 30292578
[TBL] [Abstract][Full Text] [Related]
9. Day and night glycaemic control with a bionic pancreas versus conventional insulin pump therapy in preadolescent children with type 1 diabetes: a randomised crossover trial.
Russell SJ; Hillard MA; Balliro C; Magyar KL; Selagamsetty R; Sinha M; Grennan K; Mondesir D; Ekhlaspour L; Zheng H; Damiano ER; El-Khatib FH
Lancet Diabetes Endocrinol; 2016 Mar; 4(3):233-243. PubMed ID: 26850709
[TBL] [Abstract][Full Text] [Related]
10. Comparison of dual-hormone artificial pancreas, single-hormone artificial pancreas, and conventional insulin pump therapy for glycaemic control in patients with type 1 diabetes: an open-label randomised controlled crossover trial.
Haidar A; Legault L; Messier V; Mitre TM; Leroux C; Rabasa-Lhoret R
Lancet Diabetes Endocrinol; 2015 Jan; 3(1):17-26. PubMed ID: 25434967
[TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of the predictive low glucose management system in the prevention of hypoglycaemia: protocol for randomised controlled home trial to evaluate the Suspend before low function.
Abraham MB; Nicholas JA; Ly TT; Roby HC; Paramalingam N; Fairchild J; King BR; Ambler GR; Cameron F; Davis EA; Jones TW
BMJ Open; 2016 Apr; 6(4):e011589. PubMed ID: 27084290
[TBL] [Abstract][Full Text] [Related]
12. Threshold-based insulin-pump interruption for reduction of hypoglycemia.
Bergenstal RM; Klonoff DC; Garg SK; Bode BW; Meredith M; Slover RH; Ahmann AJ; Welsh JB; Lee SW; Kaufman FR;
N Engl J Med; 2013 Jul; 369(3):224-32. PubMed ID: 23789889
[TBL] [Abstract][Full Text] [Related]
13. Flexible insulin therapy with a hybrid regimen of insulin degludec and continuous subcutaneous insulin infusion with pump suspension before exercise in physically active adults with type 1 diabetes (FIT Untethered): a single-centre, open-label, proof-of-concept, randomised crossover trial.
Aronson R; Li A; Brown RE; McGaugh S; Riddell MC
Lancet Diabetes Endocrinol; 2020 Jun; 8(6):511-523. PubMed ID: 32445738
[TBL] [Abstract][Full Text] [Related]
14. Advanced hybrid closed loop therapy versus conventional treatment in adults with type 1 diabetes (ADAPT): a randomised controlled study.
Choudhary P; Kolassa R; Keuthage W; Kroeger J; Thivolet C; Evans M; Ré R; de Portu S; Vorrink L; Shin J; Habteab A; Castañeda J; da Silva J; Cohen O;
Lancet Diabetes Endocrinol; 2022 Oct; 10(10):720-731. PubMed ID: 36058207
[TBL] [Abstract][Full Text] [Related]
15. 2 month evening and night closed-loop glucose control in patients with type 1 diabetes under free-living conditions: a randomised crossover trial.
Kropff J; Del Favero S; Place J; Toffanin C; Visentin R; Monaro M; Messori M; Di Palma F; Lanzola G; Farret A; Boscari F; Galasso S; Magni P; Avogaro A; Keith-Hynes P; Kovatchev BP; Bruttomesso D; Cobelli C; DeVries JH; Renard E; Magni L;
Lancet Diabetes Endocrinol; 2015 Dec; 3(12):939-47. PubMed ID: 26432775
[TBL] [Abstract][Full Text] [Related]
16. Day-and-night glycaemic control with closed-loop insulin delivery versus conventional insulin pump therapy in free-living adults with well controlled type 1 diabetes: an open-label, randomised, crossover study.
Bally L; Thabit H; Kojzar H; Mader JK; Qerimi-Hyseni J; Hartnell S; Tauschmann M; Allen JM; Wilinska ME; Pieber TR; Evans ML; Hovorka R
Lancet Diabetes Endocrinol; 2017 Apr; 5(4):261-270. PubMed ID: 28094136
[TBL] [Abstract][Full Text] [Related]
17. Comparing advanced hybrid closed loop therapy and standard insulin therapy in pregnant women with type 1 diabetes (CRISTAL): a parallel-group, open-label, randomised controlled trial.
Benhalima K; Beunen K; Van Wilder N; Ballaux D; Vanhaverbeke G; Taes Y; Aers XP; Nobels F; Marlier J; Lee D; Cuypers J; Preumont V; Siegelaar SE; Painter RC; Laenen A; Gillard P; Mathieu C
Lancet Diabetes Endocrinol; 2024 Jun; 12(6):390-403. PubMed ID: 38697182
[TBL] [Abstract][Full Text] [Related]
18. "Let the Algorithm Do the Work": Reduction of Hypoglycemia Using Sensor-Augmented Pump Therapy with Predictive Insulin Suspension (SmartGuard) in Pediatric Type 1 Diabetes Patients.
Biester T; Kordonouri O; Holder M; Remus K; Kieninger-Baum D; Wadien T; Danne T
Diabetes Technol Ther; 2017 Mar; 19(3):173-182. PubMed ID: 28099035
[TBL] [Abstract][Full Text] [Related]
19. Home use of a bihormonal bionic pancreas versus insulin pump therapy in adults with type 1 diabetes: a multicentre randomised crossover trial.
El-Khatib FH; Balliro C; Hillard MA; Magyar KL; Ekhlaspour L; Sinha M; Mondesir D; Esmaeili A; Hartigan C; Thompson MJ; Malkani S; Lock JP; Harlan DM; Clinton P; Frank E; Wilson DM; DeSalvo D; Norlander L; Ly T; Buckingham BA; Diner J; Dezube M; Young LA; Goley A; Kirkman MS; Buse JB; Zheng H; Selagamsetty RR; Damiano ER; Russell SJ
Lancet; 2017 Jan; 389(10067):369-380. PubMed ID: 28007348
[TBL] [Abstract][Full Text] [Related]
20. Hybrid closed-loop insulin delivery versus sensor-augmented pump therapy in children aged 6-12 years: a randomised, controlled, cross-over, non-inferiority trial.
Kariyawasam D; Morin C; Casteels K; Le Tallec C; Sfez A; Godot C; Huneker E; Garrec N; Benhamou PY; Polak M; Charpentier G; Franc S; Beltrand J
Lancet Digit Health; 2022 Mar; 4(3):e158-e168. PubMed ID: 35216750
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
